What Is Retatrutide?
Retatrutide (developmental designation LY3437943) is a synthetic peptide analog developed by Eli Lilly. It belongs to a class of compounds designed to simultaneously engage three distinct metabolic receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This tri-agonist profile sets it apart from earlier single and dual-agonist […]